Iluzanebart

艾佐奈拜单抗

Report date: 2025/06/12 20:00:09

Base Information

Drug NameIluzanebart
Drug Alias NameVGL-101VGL 101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTriggering receptor expressed on myeloid cells 2 stimulants
TargetsTriggering receptor expressed on myeloid cells 2
Therapy Area/IndicationsNerve DegenerationPosterior Leukoencephalopathy Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesVigil Neuroscience Inc
Active IndicationsNerve Degeneration
Inactive IndicationsPosterior Leukoencephalopathy Syndrome

Other Information

ATC CodeN/A
Related LinksN/A